Oncology On targeted radiotherapeutics, with Marc Hedrick Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.
Digital Towards one, cohesive AI workflow: In conversation with Ilya... In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ilya Burkov, global head of healthcare & life sciences at Nebius, about AI.
Sales & Marketing Collaborating on a connected platform journey, with Alexande... pharmaphorum speaks with Bayer's Alexander Alex and Veeva's Florian Schnappauf about Bayer's recent migration to the connected Vault CRM platform.
Oncology ESMO25: Patient-centric oncological futures with Boehringer ... On new oncology data from Boehringer Ingelheim, with Lykke Hinsch Gylvin, chief medical officer, and Itziar Canamasas, head of oncology, at ESMO 2025.
Market Access Smoothing a contract pathway through uncertainty: In convers... Today's podcast with Entity Risk's Neal Masia includes insights on the 340B Program, PBMs, and risk-based contracts.
Digital FH25: On the future of health, with Frontiers Health Chairma... In the final episode of our special Frontiers Health limited series, conference Chairman Roberto Ascione discusses his favourite moments and insights.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.